Osteoporosis
Conference Coverage
Denosumab now dominant therapy for osteoporosis linked to cancer
In changing patterns of osteoporosis drug prescriptions, denosumab has risen to the top of cancer indications.
From the Journals
Abdominal aortic calcification may further raise known fracture risk
Men with a prevalent vertebral fracture on lateral spine radiograph had even greater risk for future osteoporotic fractures with increasing...
Guidelines
Don’t discontinue osteoporosis meds for COVID-19 vaccines, expert guidance says
Recommendations help physicians distinguish between a reaction to the vaccine and a reaction to medication.
From the Journals
Bone loss common in kidney stone patients, yet rarely detected
Almost one-quarter of patients diagnosed with kidney stones have osteoporosis or a fracture history on diagnosis, yet few undergo bone mineral...
Guidelines
COVID-19 vaccination recommended for rheumatology patients
The threat posed by COVID-19 for people with rheumatic diseases outweighs concerns about vaccination against SARS-CoV-2, says the American College...
Conference Coverage
Romosozumab may not increase cardiovascular risk after all
Could a cardioprotective effect of bisphosphonates in a pivotal clinical trial of romosozumab explain why the biologic was given a black-box...
From the Journals
Cumulative exposure to high-potency topical steroid doses drives osteoporosis fractures
"A 3% increase in the relative risk of osteoporosis and MOF was observed per doubling of the TCS dose."
From the Journals
Could an osteoporosis drug reduce need for hip revision surgery?
Denosumab, widely used to treat osteoporosis, may reduce the need for revision surgery due to aseptic loosening of the prosthesis in patients with...
From the Journals
Osteoporosis prevalence in PsA similar to general population
In this longitudinal cohort study, none of the factors associated with a higher likelihood of having a bone mineral density (BMD) test were...
Guidelines
EULAR recommendations define strategies to improve adherence in RMDs
A task force put together four overarching principles and nine points to consider to address adherence to both pharmacologic and nonpharmacologic...
From the Journals
Temper enthusiasm for long-term treatment with bisphosphonates?
A real-world study of nearly 30,000 women shows no benefit, in terms of hip fracture risk, between taking oral bisphosphonates for 10 years vs. 5...